Does Wegovy work straight away, or does it take time?

What is Wegovy doing in the first week or two?

When you inject the 0.25 mg starter dose for the first time, semaglutide begins binding to GLP-1 receptors almost immediately. The receptor activity is real from day one. What is not immediate is the downstream effect on appetite and, later, on the number on the scales.

The 0.25 mg dose exists specifically so your digestive system can adjust gradually. It is a low level chosen to reduce nausea and vomiting during the body's settling-in period, not to produce the appetite suppression associated with the maintenance dose. Some people do feel slightly less hungry within the first fortnight; others notice nothing beyond mild queasiness after the injection. Both experiences are completely normal and neither predicts how well Wegovy will work for you over time.

You can read more about the mechanism behind this on our guide to how Wegovy works. The short version: GLP-1 slows gastric emptying, so food sits in the stomach longer and fullness signals reach the brain sooner. At 0.25 mg, that effect is present but gentle. Think of it like turning down the volume rather than muting a signal.

Side effects, if they appear, tend to peak in the days after an injection and fade before the next one. Nausea is the most commonly reported. Keeping the pen in the fridge door as a weekly reminder and injecting on a consistent day each week helps many people spot patterns early and manage them with small practical adjustments like eating slower or avoiding heavy meals on injection day.

When do most people start to see real appetite change?

Noticeable appetite suppression typically arrives somewhere between weeks two and eight for most people on Wegovy, though the timing varies. The first real dose step, from 0.25 mg to 0.5 mg at around four weeks, is often when people first describe feeling genuinely less interested in finishing a meal or skipping a snack they would ordinarily have reached for.

The titration schedule continues upward through 1.0 mg, 1.7 mg, and eventually 2.4 mg, with each level held for roughly four weeks. By the time someone reaches the maintenance dose, the appetite-regulating effect is substantially stronger than it was at the start. This is by design. Rushing the schedule does not produce better results and tends to make side effects harder to tolerate.

Weight loss follows appetite change with a short lag. The STEP 1 trial, published in the New England Journal of Medicine, reported an average reduction of around 15% of body weight over 68 weeks at the 2.4 mg dose. That figure accumulates across those months, not across days. It is also an average: some participants lost more, some less. Individual results depend on starting weight, adherence to lifestyle changes, and other clinical factors your prescriber considers.

For context on how Wegovy compares with tirzepatide and other options, our weight management overview covers the landscape without pushing you toward any particular choice before a clinical conversation.

Can Wegovy work straight away for some people more than others?

There is some genuine variation. People who are particularly sensitive to GLP-1 receptor activation may notice hunger changes within the first week at the starter dose, and if you are curious about whether Wegovy starts working straight away, that page walks through what the evidence shows for early responders. Others reach the 2.4 mg maintenance dose and only then feel the effect fully. Neither experience is a sign that treatment is or is not working.

A few factors that influence the timeline: body weight at baseline, metabolic rate, whether someone has type 2 diabetes (which can affect semaglutide's appetite impact), and how closely reduced-calorie eating and activity are maintained alongside the medicine. Wegovy's licence is for use alongside a reduced-calorie diet and increased activity, not as a stand-alone fix. The NHS medicines page for semaglutide covers the practical requirements of treatment clearly.

One question our prescribers hear regularly is whether slow early progress means the medicine is not working. It usually does not. The first couple of months are largely the dose-building phase. The clinical conversation at each review is the right place to raise concerns, adjust expectations, or consider whether titration should pause at a lower dose for comfort reasons.

If you are weighing up whether Wegovy suits your situation, including questions about conditions like Wegovy and lipedema or how appetite-related factors like food cravings may change on treatment, those pages lay out what the evidence does and does not support.

What does NICE say about when to assess whether Wegovy is working?

The NICE appraisal of semaglutide for weight management, TA875, recommends that treatment should be reviewed after six months at the maintenance dose. If someone has lost less than 5% of their starting body weight by that point, continuing Wegovy may not be the right call. That six-month window is deliberate: it accounts for the titration period and allows a fair test of the medicine at the dose it was designed to work at.

What this guidance makes clear is that the right question is not whether Wegovy starts working right away, but whether it is producing a meaningful clinical effect after a proper period on the maintenance dose. Checking weight at week two, while the body is still adjusting to 0.25 mg, is not a fair test and not the assessment the prescriber will be making.

The cost of private treatment is a separate consideration worth thinking through early. Our Wegovy price comparison page sets out what private Wegovy treatment typically costs and what legitimate providers include in that price, since consultation, clinical review, and aftercare all affect the total.

If you would like a prescriber to assess your suitability for Wegovy, start your free consultation with our clinical team. A GPhC-registered prescriber, not an automated system, reads every submission the same day.